Montelukast alleviates thioacetamide-induced hepatic encephalopathy in rats
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04291-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Rehab S Abdelrahman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. Hauptthemen laut MEDLINE: Quinolines, Acetates, Hepatic Encephalopathy, Leukotriene Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
Hepatic encephalopathy (HE) is a serious neuropsychiatric dysfunction associated with acute and chronic liver disease. Montelukast (Mon) is a cysteinyl leukotriene receptor 1 (CysLT1R) antagonist approved as adjuvant therapy for asthma. The antioxidant and anti-inflammatory effects of montelukast have been reported in previous studies. To the best of our knowledge, Mon therapeutics' efficacy against thioacetamide-induced HE has not been investigated. This study aims to detect the protective effects of Mon (5 and 10 mg/kg, orally for seven consecutive days) on TAA (200 mg/kg, i.p., at three alternative days) induced HE in rats and to demonstrate its hepato/neuroprotective effects mechanisms. Results showed that Mon significantly improved hepatic and brain function, suppressed the release of inflammatory factors (brain and liver levels of NF-κB and TNF-α), and reduced oxidative stress (MDA and NO levels in both the brain and liver). Moreover, Mon activated PI3K/Akt expression in the brain and suppressed TAA-induced brain caspase-3 expression. Finally, TAA-induced histopathological changes in brain and liver sections were markedly normalized by Mon. Mon shows promise as a therapeutic agent in experimental HE models, and its mechanism of action involves the upregulation of PI3K/Akt expression, thereby inhibiting the expression of caspase-3 and the activity of TNF-α and NF-κB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Taibah University, 41477, Al-Madina Al-Munawwarah, Saudi Arabia.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt. rania200582@yahoo.com.
Zitieren
APA
Abdelrahman, R. S., Abdelaziz, R. R., & Abdelmageed, M. E. (2025). Montelukast alleviates thioacetamide-induced hepatic encephalopathy in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04291-9
Vancouver
Abdelrahman RS, Abdelaziz RR, Abdelmageed ME. Montelukast alleviates thioacetamide-induced hepatic encephalopathy in rats. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04291-9
BibTeX
@article{Abdelrahman2025,
author = {Abdelrahman, Rehab S and Abdelaziz, Rania R and Abdelmageed, Marwa E},
title = {Montelukast alleviates thioacetamide-induced hepatic encephalopathy in rats},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04291-9}
}
EUVIMED